Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study

13 Nov 2023

Abstract excerpt

Acute myeloid leukemia (AML) with AML1/ETO-positive or translocation (8;21) (AE-AML) has been shown clinical heterogeneity [ 1 , 2 , 3 , 4 ] and is necessary to be further stratified. Numerous studies [ 3 , 5 , 6 , 7 ] reveal the importance of measurable residual disease (MRD) as a prognostic predictor in guiding tailor treatment of AE-AML, that patients with high MRD levels are categorized as high-risk and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to CAR-T cell therapy research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37957175
DOI: 10.1038/s41408-023-00941-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort studyPMID 37957175Read ↗

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia PatientsSemantic proximity Read ↗

AML1-ETO-positive acute myeloid leukemia presents different phenotype in pediatric and adult patientsSemantic proximity Read ↗

Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.Semantic proximity Read ↗

Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia.Semantic proximity Read ↗

The new provisional WHO entity ‘RUNX1 mutated AML’ shows specific genetics but no prognostic influence of dysplasiaSemantic proximity Read ↗

Allogeneic transplantation for AML with RUNX1::RUNX1T1 fusion: a time-dependent analysis in a retrospective studySemantic proximity Read ↗

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.Semantic proximity Read ↗

AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations.Semantic proximity Read ↗

Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.Semantic proximity Read ↗

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studySemantic proximity Read ↗

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.Semantic proximity Read ↗

Allogeneic haematopoietic stem cell transplantation can improve the prognosis of high-risk paediatric t(8;21) acute myeloid leukaemia in first remission based on MRD-guided treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.